Company Statements

FOSTER CITY, Calif., May 1, 2017 — Gilead Sciences, Inc. today announced that it issued its Year in Review 2016, a combination of the company's Annual Report and Corporate Social Responsibility report. This report provides an in-depth look into Gilead's commitment to develop and deliver innovative therapies that change lives.

The report focuses on four key areas: giving and access, people, products and environment as well as a financial overview. Highlights include:

• Giving & Access: In 2016, Gilead provided almost $460 million in cash donations to more than 2,000 organizations worldwide to address unmet medical needs and lessen the impact of diseases such as HIV and viral hepatitis around the world. In ten years, Gilead has been able to increase the number of people receiving the company's antiretroviral therapies in the developing world from fewer than 30,000 people in 2006 to 10 million in 2016.
• People: Gilead added "inclusion" to the company's core values in 2016, reinforcing its commitment to workforce diversity, which drives innovation. Gilead added 657 jobs to local communities around the world in 2016, representing a year-over-year growth rate of eight percent.
• Products: Gilead continued to transform patient care in 2016 with the launch of four therapies - two for HIV and two for viral hepatitis - representing important advances for people living with these life-threatening diseases. With more than 20 marketed products, Gilead produced and distributed 33 million bottles of oral medicines and approximately 11 million vials of liquid medicine worldwide in 2016.
• Environment: Gilead achieved zero waste to landfill in 2016 at corporate sites in Cork, Ireland, Stockley Park, U.K. and Cambridge, U.K. At its Foster City, California headquarters, Gilead achieved a 66 percent annual waste diversion rate.

To download the report, visit the Annual Report page